Value of CA 15-3 in Female Patients with Breast Cancer
Rashed, S., Seddek, O., Abo- El Wafa, H., Mohamed, A. (2018). Value of CA 15-3 in Female Patients with Breast Cancer. EKB Journal Management System, 22(2), 165-170. doi: 10.21608/smj.2018.40071
Shimaa A Rashed; Osama B Seddek; Hasnaa Ahmed Abo- El Wafa; Abeer M Mohamed. "Value of CA 15-3 in Female Patients with Breast Cancer". EKB Journal Management System, 22, 2, 2018, 165-170. doi: 10.21608/smj.2018.40071
Rashed, S., Seddek, O., Abo- El Wafa, H., Mohamed, A. (2018). 'Value of CA 15-3 in Female Patients with Breast Cancer', EKB Journal Management System, 22(2), pp. 165-170. doi: 10.21608/smj.2018.40071
Rashed, S., Seddek, O., Abo- El Wafa, H., Mohamed, A. Value of CA 15-3 in Female Patients with Breast Cancer. EKB Journal Management System, 2018; 22(2): 165-170. doi: 10.21608/smj.2018.40071

Value of CA 15-3 in Female Patients with Breast Cancer

Sohag Medical Journal
Article 21, Volume 22, Issue 2, July 2018, Page 165-170  XML PDF (70.73 K)
Document Type: Original Article
DOI: 10.21608/smj.2018.40071
View on SCiNiTO View on SCiNiTO
Authors
Shimaa A Rashed1; Osama B Seddek1; Hasnaa Ahmed Abo- El Wafa2; Abeer M Mohamed1
1Department, of Clinical Pathology, Faculty of Medicine, Sohag University.
2Department of Clinical Pathology,Faculty of Medicine, Sohag University.
Abstract
Introduction: Breast cancer (BC) is most common cancer site in women worldwide. The CA 15-3 is tumor associated antigen which detects soluble forms of MUC-1 protein. In normal breast tissue MUC-1 is expressed in the duct and acini, but with neoplastic transformation normal cell polarization and tissue architecture is disrupted leading to shedding of MUC-1 in the blood, where it can be measured by immunoassay. It is the most widely used serum marker in patients with BC. Its main use is for monitoring therapy in patients with metastatic disease.
Aim of the work: Aim of this work was to detect the diagnostic value of CA 15-3 in female patients with BC.
Patients and Methods: This study was carried on one hundred women, included fifty female patients with BC presented to Medical Oncology Department at Sohag University Hospital from 2015 to 2017, their age ranged from (25-70 years). Patients were diagnosed by clinical examination and confirmed by mammography and surgical biopsies; fine needle aspiration cytology (FNAC) or core needle biopsy (CNB) and CA15-3. Other fifty women were 25 healthy control not relatives to the patients and the other 25 were first degree relatives to the patients.
Results: Our study suggested that CA 15-3 is abnormal in the majority of patients with breast cancer.
Conclusion: Serum markers in BC are helpful for clinicians in providing more effective management of the disease. To this end, different markers have been proposed in the last years. In particular, MUC1 (CA 15-3) is the most widely used and investigated in the breast cancer follow-up period.
Keywords
CA 15-3; breast cancer
Supplementary Files
References
1.Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patt erns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49:1374-403.

2. Hrvatski zavod za javno zdravstvo. Registar za rak. Incidencija raka u Hrvatskoj 2013. Bilten 2015;38.

3. Gagnon, J., et al. “Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current   policies.” Current Oncology 23.6 (2016): e615.

4. Vasconcelos, Ines, et al. “The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.” The Breast 29 (2016):18-185.

5. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. ClinChim Acta. 2010 Dec 14;411(23-24):1869-74.

6. Nikhil G Thaker, Dolly R, Dina FC, Eric BS (2014): CA 15-3 reference range. emedicine Medscape article 2087491. 2014; 1-2.

7. Bast RC, Ravdin P, Hayes DF. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinican Oncology. J Clin Onc 2001; 19(6): 1865-78.

8.  Knudson AG. Two genetic hits (more or less) to cancer. Nature reviews Cancer. 2001;1(2):157-62.

9.  Jalkh N, Nassar-Slaba J, Chouery E, Salem N, Uhrchammer N, Golmard L, et al. Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon. Hereditary cancer in clinical practice. 2012;10(1):7.

10.       Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. Journal of the National Cancer Institute. 1999;91(11):943-9.

11. Vali A, Ivan Milas, Ljiljana Mayer. Prognostic Significance Of Ca 15-3 Tumor Marker In Breast Cancer Patients. Libri Oncol. 2017;45(1):1–8.

12. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19:67581.

13. Moazzezy N, Farahany TZ, Oloomi M, Bouzari S. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev. 2014;15(4):1685-8.

14. Duffy MJ, Duggan C, Keane R, Hill AD, McDermott E, Crown J, O’Higgins N. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative

and node positive breast cancer: study of 600 patients with histologically confi rmed breast cancer. Clin Chem. 2004;50:559-63.

15. Ebeling FG, Stieber P, Untch M, Nagel D, Konecny GE, Schmitt UM, Fateh-Moghadam A, Seidel D. Serum CEA and CA 15-3 as prognostic factors in primary

breast cancer. Br J Cancer. 2002;86:1217-22.

Statistics
Article View: 184
PDF Download: 237